Journey Medical (NASDAQ:DERM) Announces Earnings Results

Journey Medical (NASDAQ:DERM) issued its earnings results on Wednesday. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.30, Zacks reports. The company had revenue of $14.30 million for the quarter, compared to analyst estimates of $14.21 million. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%.

Journey Medical Stock Up 1.4 %

Shares of NASDAQ:DERM traded up $0.08 on Friday, reaching $6.00. The company had a trading volume of 19,555 shares, compared to its average volume of 86,301. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. The stock has a market capitalization of $125.36 million, a P/E ratio of -6.38 and a beta of 0.97. The stock has a 50-day moving average price of $5.05 and a 200 day moving average price of $5.16. Journey Medical has a twelve month low of $3.20 and a twelve month high of $6.89.

Insider Activity at Journey Medical

In other Journey Medical news, CEO Claude Maraoui sold 18,147 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $5.13, for a total transaction of $93,094.11. Following the transaction, the chief executive officer now owns 2,092,874 shares in the company, valued at $10,736,443.62. This trade represents a 0.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In the last ninety days, insiders have sold 105,831 shares of company stock valued at $536,622. Corporate insiders own 13.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Alliance Global Partners restated a “buy” rating on shares of Journey Medical in a report on Thursday. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $9.67.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.